[Effect of anti-HPV16 E6-ribozyme on cell proliferation and invasiveness of cervical carcinoma cell line CaSKi].
OBJECTIVE
To investigate the effects of anti-HPV16-ribozyme on the cell proliferation and invasiveness of cultured cervical cancer cell line CaSKi.


METHODS
CaSKi cells were transfected with anti-HPV16 E6-ribozyme and empty eukaryotic expression plasmids via lipofectin and designated as CaSKi-R and CaSKi-P cells respectively. The growth rate, cell colony-forming ability on soft agar, invasiveness and tumorigenicity of CaSKi-R, CaSKi-P, and CaSKi cells were studied using corresponding methods. The expressions of cox-2 and vascular endothelial growth factor (VEGF) mRNA of the 3 cell strains were determined with one-step reverse transcriptional PCR (RT-PCR), and immunocytochemistry was employed for detecting the expressions of COX-2 and VEGF antigens.


RESULTS
No distinct differences in the growth rate, colony-forming ability on soft agar, cell invasiveness and tumorigenicity were observed between CaSKi and CaSKi-P cells, whereas by comparison, CaSKi-R cells exhibited decreased growth rate, colony-forming ability, the cell invasiveness and tumorgenicity, with also lowered expression levels of cox-2 and VEGF mRNA as shown by RT-PCR analysis. Expressions of COX-2 and VEGF antigens were detected in all the 3 cell strains immunocytochemically, but compared with CaSKi and CaSKi-P cells, the antigen expressions in CaSKi-R cells were significantly weaker.


CONCLUSIONS
Anti-HPV16 E6-ribozyme may partially inhibit the proliferation and reduce the invasiveness of CaSKi cells possibly through decreasing cox-2 and VEGF expressions, which are the important agents for tumor invasion.
Liu
Ke
K
Department of Obstetrics and Gynecology, People's Hospital of Huadu District, Guangzhou 510800, China. liuke76@yahoo.com.cn
Wang
Li-li
LL
Sun
Fang
F
Zheng
Yan-fang
YF
Zhang
Ji-ren
JR
D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D005260:Female; D006801:Humans; D009361:Neoplasm Invasiveness; D009856:Oncogene Proteins, Viral / Q000037:antagonists & inhibitors*; D011505:Protein-Tyrosine Kinases; D016337:RNA, Catalytic / Q000494:pharmacology*; D012097:Repressor Proteins / Q000037:antagonists & inhibitors*; D014162:Transfection; D002583:Uterine Cervical Neoplasms / Q000473:pathology*
C068651:E6 protein, Human papillomavirus type 16; D009856:Oncogene Proteins, Viral; D016337:RNA, Catalytic; D012097:Repressor Proteins; D011505:Protein-Tyrosine Kinases